{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:36:03Z","timestamp":1789180563884,"version":"build-2803163510"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"21","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204207"],"award-info":[{"award-number":["82204207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-026"],"award-info":[{"award-number":["2021-I2M-1-026"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332025072"],"award-info":[{"award-number":["3332025072"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332025166"],"award-info":[{"award-number":["3332025166"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Given the urgent need to combat HIV-1 drug resistance, we designed and synthesized a novel series of HIV-1 protease inhibitors with modified core scaffolds, including amino acid-linked hydroxyethyl sulfonamide, hydroxyethyl sulfonimidamide, and hydroxyethyl phosphonamidite. Most of these compounds exhibited potent activities in both enzymatic and cellular assays. Notably, compound 20a, featuring an extended l-asparagine linker, displayed an enzymatic IC50 of 10 pM and an antiviral EC50 of 10.4 nM. Furthermore, it maintained excellent potency against the multidrug-resistant variants (EC50 = 30 \u223c 34.3 nM), demonstrating a superior resistance profile relative to Darunavir. Molecular modeling revealed that the introduction of the l-asparagine fragment promoted extensive interactions with various residues throughout the protease active site. Subsequent investigations indicated that compound 20a-D, the dipeptide prodrug of 20a, exhibited improved ADME properties. Consequently, this study highlighted the potential of core scaffold modification in generating candidates to overcome multidrug resistance and provided valuable information for further optimization.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01484","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:19:59Z","timestamp":1761164399000},"page":"22547-22568","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis,\nand Biological Evaluation of Novel\nCore Scaffold-Modified HIV-1 Protease Inhibitors for Overcoming\nDrug Resistance"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4294-6517","authenticated-orcid":true,"given":"Huiyu","family":"Zhou","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Weifang People\u2019s Hospital , ,","place":["Weifang, China, 261000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shan","sequence":"additional","affiliation":[{"name":"Tianjin Institute of Pharmaceutical Research , ,","place":["Tianjin, China, 300462"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Meng","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Dong","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxian","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-0411","authenticated-orcid":true,"given":"Shan","family":"Cen","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2124-594X","authenticated-orcid":true,"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-2754","authenticated-orcid":true,"given":"Yongsheng","family":"Che","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Beijing, P. R. China, 100050"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"4","key":"2026073103230865900_cit1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrmicro2747","article-title":"The structural\nbiology of HIV-1: mechanistic and therapeutic\ninsights","volume":"10","author":"Engelman","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"issue":"9939","key":"2026073103230865900_cit2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection:\nepidemiology, pathogenesis,\ntreatment, and prevention [published correction appears in Lancet.\n2014 Sep 20;384(9948):1098]","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet."},{"key":"2026073103230865900_cit3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis Primers."},{"key":"2026073103230865900_cit4","unstructured":"Ghosh, A. K.; Anderson, D. D.; Mitsuya, H.\n          The FDA Approved\nHIV-1 Protease Inhibitors for Treatment of HIV\/AIDS\n          Burger\u2019s Medicinal Chemistry and Drug Discovery\n          2003, pp 1\u201374."},{"issue":"11","key":"2026073103230865900_cit5","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent Progress in\nthe Development\nof HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026073103230865900_cit6","volume-title":"HIV\nDrug Resistance: Brief Report 2024","year":"2024"},{"key":"2026073103230865900_cit7","volume-title":"Guidelines\non the Public Health Response to Pretreatment HIV Drug Resistance,\nJuly 2017","year":"2017"},{"issue":"7","key":"2026073103230865900_cit8","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","article-title":"Dolutegravir\nplus boosted darunavir versus recommended standard-of-care antiretroviral\nregimens in people with HIV-1 for whom recommended first-line non-nucleoside\nreverse transcriptase inhibitor therapy has failed (D2EFT):\nan open-label, randomised, phase 3b\/4 trial","volume":"11","author":"D2EFT Study Group.","year":"2024","journal-title":"Lancet HIV."},{"key":"2026073103230865900_cit9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/DDDT.S443775","article-title":"Outcome of Darunavir-Cobicistat-Based\nRegimens in HIV-Infected People Who Have Experienced Virological Failure","volume":"18","author":"Alberton","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"issue":"3","key":"2026073103230865900_cit10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.antiviral.2007.06.010","article-title":"Protease inhibitor resistance in HIV-infected patients:\nmolecular and clinical perspectives","volume":"76","author":"Martinez-Cajas","year":"2007","journal-title":"Antiviral\nRes."},{"issue":"12","key":"2026073103230865900_cit11","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1093\/jac\/dkw343","article-title":"HIV-1\ndrug resistance mutations emerging on darunavir therapy in PI-naive\nand -experienced patients in the UK","volume":"71","author":"El Bouzidi","year":"2016","journal-title":"J. Antimicrob.\nChemother."},{"issue":"1","key":"2026073103230865900_cit12","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02354-6","article-title":"Resistance to protease\ninhibitors among persons living with HIV in Ghana: a case for viral\nload and drug resistance monitoring","volume":"21","author":"Seshie","year":"2024","journal-title":"Virol.\nJ."},{"issue":"1","key":"2026073103230865900_cit13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of\nHIV protease\ninhibitors targeting protein backbone: an effective strategy for combating\ndrug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"8","key":"2026073103230865900_cit14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/anie.201102762","article-title":"Enhancing protein backbone\nbinding--a fruitful concept for combating drug-resistant HIV","volume":"51","author":"Ghosh","year":"2012","journal-title":"Angew. Chem., Int. Ed. Engl."},{"issue":"5","key":"2026073103230865900_cit15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/acsbiomedchemau.4c00040","article-title":"Design,\nSynthesis, and Biological Evaluation of Darunavir Analogs as HIV-1\nProtease Inhibitors","volume":"4","author":"Ur Rehman","year":"2024","journal-title":"ACS Bio Med. Chem. Au."},{"issue":"36","key":"2026073103230865900_cit16","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1039\/D4OB00506F","article-title":"Design of substituted tetrahydrofuran derivatives\nfor HIV-1 protease inhibitors: synthesis, biological evaluation, and\nX-ray structural studies","volume":"22","author":"Ghosh","year":"2024","journal-title":"Org. Biomol. Chem."},{"key":"2026073103230865900_cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129651","article-title":"Rational design, synthesis and biological evaluation\nof novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives\nas P2 ligands with potent activity against DRV-Resistant HIV-1 variants","volume":"101","author":"Meng","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026073103230865900_cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2025.130109","article-title":"Potent HIV-1 protease\ninhibitors containing oxabicyclo octanol-derived P2-ligands: Design,\nsynthesis, and X-ray structural studies of inhibitor-HIV-1 protease\ncomplexes","volume":"120","author":"Ghosh","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"2026073103230865900_cit19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/chir.23376","article-title":"New pharmaceuticals approved by FDA in 2020:\nSmall-molecule drugs derived from amino acids and related compounds","volume":"34","author":"Liu","year":"2022","journal-title":"Chirality."},{"key":"2026073103230865900_cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113448","article-title":"Tailor-made amino acids in the design of small-molecule blockbuster\ndrugs","volume":"220","author":"Han","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"2026073103230865900_cit21","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1021\/acs.jmedchem.7b01709","article-title":"Identification of Highly\nPotent Human Immunodeficiency Virus Type-1 Protease Inhibitors against\nLopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based\nPeptidomimetics with P2 Tetrahydrofuranylglycine","volume":"61","author":"Hidaka","year":"2018","journal-title":"J. Med. Chem."},{"issue":"36","key":"2026073103230865900_cit22","doi-asserted-by":"publisher","first-page":"9399","DOI":"10.1002\/anie.201302209","article-title":"Sulfoximines:\na neglected opportunity in medicinal chemistry","volume":"52","author":"Lu\u0308cking","year":"2013","journal-title":"Angew. Chem., Int. Ed. Engl."},{"issue":"23","key":"2026073103230865900_cit23","doi-asserted-by":"publisher","first-page":"14243","DOI":"10.1021\/acs.jmedchem.0c00960","article-title":"Sulfoximines as Rising\nStars in Modern Drug Discovery?\nCurrent Status and Perspective on an Emerging Functional Group in\nMedicinal Chemistry","volume":"63","author":"Ma\u0308der","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026073103230865900_cit24","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/jo001699u","article-title":"Synthesis\nof novel 3\u2032-C-methylene\nthymidine and 5-methyluridine\/cytidine H-phosphonates and phosphonamidites\nfor new backbone modification of oligonucleotides","volume":"66","author":"An","year":"2001","journal-title":"J. Org. Chem."},{"issue":"9","key":"2026073103230865900_cit25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.4155\/fmc-2019-0331","article-title":"Synthesis and evaluation of potent human immunodeficiency\nvirus 1 protease inhibitors with epimeric isopropanol as novel P1\u2032\nligands","volume":"12","author":"Zhu","year":"2020","journal-title":"Future Med. Chem."},{"key":"2026073103230865900_cit26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113498","article-title":"Design and biological\nevaluation of cinnamic and phenylpropionic amide derivatives as novel\ndual inhibitors of HIV-1 protease and reverse transcriptase","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2026073103230865900_cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115389","article-title":"Design,\nsynthesis, and biological evaluation\nof novel HIV-1 protease inhibitors containing pyrrolidine-derived\nP2 ligands to combat drug-resistant variant","volume":"255","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"2026073103230865900_cit28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1021\/jm010349c","article-title":"New strategy\nfor antedrug\napplication: development of metalloproteinase inhibitors as antipsoriatic\ndrugs","volume":"45","author":"Sawa","year":"2002","journal-title":"J. Med. Chem."},{"key":"2026073103230865900_cit29","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1002\/adsc.202100162","article-title":"Regio- and Stereoselective Chloro Sulfoximidations\nof Terminal Aryl Alkynes Enabled by Copper Catalysis and Visible Light","volume":"363","author":"Shi","year":"2021","journal-title":"Adv. Synth. Catal."},{"issue":"25","key":"2026073103230865900_cit30","doi-asserted-by":"publisher","first-page":"7203","DOI":"10.1002\/anie.201602320","article-title":"Transfer\nof Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis\nof NH Sulfoximines from Sulfoxides","volume":"55","author":"Zenzola","year":"2016","journal-title":"Angew. Chem.,\nInt. Ed. Engl."},{"issue":"4945","key":"2026073103230865900_cit31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1126\/science.2106161","article-title":"Novel fluorogenic substrates\nfor assaying retroviral proteases by resonance energy transfer","volume":"247","author":"Matayoshi","year":"1990","journal-title":"Science"},{"key":"2026073103230865900_cit32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114251","article-title":"Design, synthesis and\nbiological evaluation of protease inhibitors containing morpholine\ncores with remarkable potency against both HIV-1 subtypes B and C","volume":"233","author":"Zhu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026073103230865900_cit33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.antiviral.2008.12.004","article-title":"High-throughput\nscreening using pseudotyped\nlentiviral particles: a strategy for the identification of HIV-1 inhibitors\nin a cell-based assay","volume":"81","author":"Garcia","year":"2009","journal-title":"Antiviral Res."},{"issue":"10","key":"2026073103230865900_cit34","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1128\/AAC.00574-10","article-title":"HIV-1 protease mutations\nand protease inhibitor cross-resistance","volume":"54","author":"Rhee","year":"2010","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"2","key":"2026073103230865900_cit35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/AAC.00909-07","article-title":"Factors associated with\nthe selection of mutations conferring resistance to protease inhibitors\n(PIs) in PI-experienced patients displaying treatment failure on darunavir","volume":"52","author":"Lambert-Niclot","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"22","key":"2026073103230865900_cit36","doi-asserted-by":"publisher","first-page":"11961","DOI":"10.1128\/JVI.00967-10","article-title":"In vitro selection of\nhighly darunavir-resistant and replication-competent HIV-1 variants\nby using a mixture of clinical HIV-1 isolates resistant to multiple\nconventional protease inhibitors","volume":"84","author":"Koh","year":"2010","journal-title":"J. Virol."},{"issue":"3","key":"2026073103230865900_cit37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd3367","article-title":"Probing the\nlinks between in vitro potency, ADMET and physicochemical parameters","volume":"10","author":"Gleeson","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"2026073103230865900_cit38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity\nand its relationship\nwith passive drug permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharm. Res."},{"key":"2026073103230865900_cit39","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00061","article-title":"Unique Flap Conformation in an HIV-1 Protease\nwith High-Level Darunavir Resistance","volume":"7","author":"Nakashima","year":"2016","journal-title":"Front.\nMicrobiol."},{"issue":"45","key":"2026073103230865900_cit40","doi-asserted-by":"publisher","first-page":"15993","DOI":"10.1073\/pnas.1414063111","article-title":"Structural basis\nand distal effects of Gag substrate coevolution in drug resistance\nto HIV-1 protease","volume":"111","author":"O\u0308zen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.\nS. A."},{"key":"2026073103230865900_cit41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1039\/a809656b","article-title":"A water-soluble tetrazolium\nsalt useful for colorimetric cell viability assay","volume":"36","author":"Tominaga","year":"1999","journal-title":"Anal. Commun."},{"key":"2026073103230865900_cit42","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate\npharmacokinetics, drug-likeness and medicinal chemistry friendliness\nof small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"2026073103230865900_cit43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols,\nand influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"2","key":"2026073103230865900_cit44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1021\/jm9507183","article-title":"A novel,\npicomolar inhibitor\nof human immunodeficiency virus type 1 protease","volume":"39","author":"Sham","year":"1996","journal-title":"J. Med. Chem."},{"issue":"9\u201310","key":"2026073103230865900_cit45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","article-title":"Bridging solubility between drug\ndiscovery and development","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov. Today."},{"issue":"6","key":"2026073103230865900_cit46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00003088-200342060-00002","article-title":"Metabolic\nstability for drug discovery\nand development: pharmacokinetic and biochemical challenges","volume":"42","author":"Masimirembwa","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"2026073103230865900_cit47","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1021\/jm901371v","article-title":"Physicochemical space\nfor optimum oral bioavailability: contribution of human intestinal\nabsorption and first-pass elimination","volume":"53","author":"Varma","year":"2010","journal-title":"J. Med.\nChem."},{"issue":"1","key":"2026073103230865900_cit48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10517-011-1457-y","article-title":"Comparative analysis of esterase\nactivities of human, mouse, and rat blood","volume":"152","author":"Rudakova","year":"2011","journal-title":"Bull.\nExp. Biol. Med."},{"issue":"10","key":"2026073103230865900_cit49","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.addr.2012.10.001","article-title":"Amino acids\nas promoieties\nin prodrug design and development","volume":"65","author":"Vig","year":"2013","journal-title":"Adv. Drug\nDeliv. Rev."},{"key":"2026073103230865900_cit50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ejmech.2017.07.044","article-title":"Design strategies\nin the prodrugs\nof HIV-1 protease inhibitors to improve the pharmaceutical properties","volume":"139","author":"Subbaiah","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"2026073103230865900_cit51","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/jps.23193","article-title":"Stereoselective\nevasion of P-glycoprotein, cytochrome\nP450 3A, and hydrolases by peptide prodrug modification of saquinavir","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"2026073103230865900_cit52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2005.06.017","article-title":"Evasion of P-gp mediated cellular\nefflux and permeability\nenhancement of HIV-protease inhibitor saquinavir by prodrug modification","volume":"303","author":"Jain","year":"2005","journal-title":"Int. J. Pharm."},{"key":"2026073103230865900_cit53","unstructured":"Stanford HIV drug resistance database. https:\/\/hivdb.stanford.edu\/pages\/3DStructures\/pr.html."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01484","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22547\/66300801\/acs.jmedchem.5c01484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22547\/66300801\/acs.jmedchem.5c01484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:23:17Z","timestamp":1785482597000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/21\/22547\/5235099\/Design-Synthesis-and-Biological-Evaluation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":53,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,11,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01484","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}